Towards diagnostic application of non-coding RNAs in neuroblastoma

Expert Rev Mol Diagn. 2016 Dec;16(12):1307-1313. doi: 10.1080/14737159.2016.1256207. Epub 2016 Nov 15.

Abstract

Neuroblastoma is a solid cancer of childhood, which is devastating upon recurrence. Markers for minimal residual disease and early detection of relapse are eagerly awaited to improve the outcome of affected patients. Several miRNAs have been identified as key regulators of neuroblastoma pathogenesis. Areas covered: Here, we focus on miRNAs that have been linked to MYCN, a prominent oncogenic driver, and we review the hitherto known interactions between miRNAs and other important players in neuroblastoma. Expert commentary: Existing diagnostic miRNA signatures remain to be established in clinical settings. Moreover, inhibition of individual oncogenic miRNAs or enhancement of tumor suppressive miRNA function could represent a new therapeutic approach in cancer treatment, including NB.

Keywords: Neuroblastoma; RNA sequencing; miRNA; non-coding RNA; qPCR.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor*
  • Cell Communication / genetics
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Genes, Tumor Suppressor
  • High-Throughput Nucleotide Sequencing
  • Humans
  • MicroRNAs / genetics
  • N-Myc Proto-Oncogene Protein / genetics
  • Neuroblastoma / diagnosis*
  • Neuroblastoma / genetics*
  • Neuroblastoma / therapy
  • Oncogenes
  • RNA, Untranslated / genetics*
  • Real-Time Polymerase Chain Reaction
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • MicroRNAs
  • N-Myc Proto-Oncogene Protein
  • RNA, Untranslated